Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Employer
-
Field
-
If you want to advance your career with a leader, consider Roche. We rank among the worlds foremost corporations providing innovative healthcare solutions, continuously investing in medical research and development. By preventing, diagnosing and treating a range of health disorders, our products...
-
to the President of ETH Zurich, Prof. Dr. Joël Mesot. The closing date for applications is 15 November 2025. Where to apply Website https://academicpositions.com/ad/eth-zurich/2025/assistant-professor-tenure-tra
-
) for engineering systems. Our research covers surrogate modeling, reliability analysis, sensitivity analysis, optimization under uncertainty, and Bayesian calibration. We are known for developing the UQLab software
-
. The candidate will join our multi-disciplinary team and focus on the development and performance of modern assays to evaluate bioactive molecules targeting major signaling pathways in cancer and inflammation
-
the admission requirements for a PhD at ETH Zurich Experience in machine learning, optimization, or AI-driven decision-making Preferably with knowledge of Bayesian optimization or Gaussian processes
-
) for engineering systems. Our research covers surrogate modeling, reliability analysis, sensitivity analysis, optimization under uncertainty, and Bayesian calibration. We are known for developing the UQLab software
-
recovery trajectories and injury patterns. Integrate personalized physiological measurements into a recovery prediction model, while adapting Bayesian Neural Networks for SCI data and analyzing the impact on
-
-makers, while actively providing the team with industry insights, contributing to successfully positioning Tethys Robotics among target customers Representing our technologically complex products in
-
steroidogenesis a critical target for chemical-induced endocrine disruption. By disturbing steroid biosynthesis EDCs are posing risks for metabolic, immune, neuronal and long-term reproductive diseases in both
-
, is a consortium composed of eight universities, four research institutes, and four companies from EU countries, the UK, and Switzerland. The mission of FADOS is to achieve targeted modification